OrbiMed Advisors
Latest statistics and disclosures from Orbimed Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are EWTX, SVA, LLY, BSX, ISRG, and represent 27.76% of Orbimed Advisors's stock portfolio.
- Added to shares of these 10 stocks: Mbx Biosciences (+$99M), UNH (+$39M), SRPT (+$39M), AMGN (+$38M), UHS (+$36M), Bioage Labs (+$30M), ITGR (+$29M), SYK (+$27M), PHAT (+$26M), CGON (+$26M).
- Started 21 new stock positions in Biomx, PEPG, UHS, Ardent Health Partners, OSCR, CGON, GILD, AVTX, SAVA, PHAT. LBPH, MEDP, BNTX, CRBP, MRNA, TIL, Bicara Therapeutics, Bioage Labs, ACAD, Mbx Biosciences, Traws Pharma.
- Reduced shares in these 10 stocks: JANX (-$78M), THC (-$65M), PCVX (-$47M), GERN (-$42M), VRNA (-$41M), DXCM (-$33M), ELV (-$32M), TMO (-$29M), ISRG (-$29M), HRTX (-$23M).
- Sold out of its positions in ALXO, BMRN, PHGE, DXCM, DVAX, HRTX, CATX, MORF, TRAW, ORIC. PFE, PGNY, OMIC, TGTX, VRNA, APLM, LSB, MRUS.
- Orbimed Advisors was a net seller of stock by $-36M.
- Orbimed Advisors has $5.5B in assets under management (AUM), dropping by 8.89%.
- Central Index Key (CIK): 0001055951
Tip: Access up to 7 years of quarterly data
Positions held by OrbiMed Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Orbimed Advisors
Orbimed Advisors holds 113 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics (EWTX) | 7.3 | $401M | 15M | 26.69 |
|
|
| Sinovac Biotech SHS (SVA) | 6.2 | $340M | 2.7M | 125.06 |
|
|
| Eli Lilly & Co. (LLY) | 5.4 | $299M | 338k | 885.94 |
|
|
| Boston Scientific Corporation (BSX) | 5.0 | $274M | 3.3M | 83.80 |
|
|
| Intuitive Surgical Com New (ISRG) | 3.9 | $213M | -12% | 434k | 491.27 |
|
| Enliven Therapeutics (ELVN) | 3.7 | $203M | 8.0M | 25.54 |
|
|
| Biogen Idec (BIIB) | 2.9 | $158M | -9% | 813k | 193.84 |
|
| Merck & Co (MRK) | 2.7 | $149M | 1.3M | 113.56 |
|
|
| Tenet Healthcare Corp Com New (THC) | 2.4 | $130M | -33% | 782k | 166.20 |
|
| Sarepta Therapeutics (SRPT) | 2.3 | $126M | +44% | 1.0M | 124.89 |
|
| Stryker Corporation (SYK) | 2.3 | $124M | +28% | 344k | 361.26 |
|
| Silverback Therapeutics (SPRY) | 2.2 | $120M | -10% | 8.3M | 14.50 |
|
| Argenx Se Sponsored Adr (ARGX) | 2.0 | $111M | -2% | 205k | 542.08 |
|
| UnitedHealth (UNH) | 1.9 | $105M | +59% | 179k | 584.68 |
|
| Q32 Bio (QTTB) | 1.8 | $101M | 2.3M | 44.62 |
|
|
| Mbx Biosciences | 1.8 | $99M | NEW | 3.8M | 25.98 |
|
| Ionis Pharmaceuticals (IONS) | 1.7 | $93M | -2% | 2.3M | 40.06 |
|
| Disc Medicine (IRON) | 1.6 | $88M | 1.8M | 49.14 |
|
|
| Natera (NTRA) | 1.6 | $87M | 688k | 126.95 |
|
|
| Amgen (AMGN) | 1.5 | $81M | +87% | 252k | 322.21 |
|
| Third Harmonic Bio (THRD) | 1.4 | $78M | 5.8M | 13.55 |
|
|
| Integer Hldgs (ITGR) | 1.4 | $75M | +64% | 575k | 130.00 |
|
| Arrivent Biopharma (AVBP) | 1.3 | $71M | 3.0M | 23.50 |
|
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.3 | $70M | 151k | 465.08 |
|
|
| Alnylam Pharmaceuticals (ALNY) | 1.3 | $69M | 250k | 275.03 |
|
|
| Terns Pharmaceuticals (TERN) | 1.1 | $63M | 7.6M | 8.34 |
|
|
| Keros Therapeutics (KROS) | 1.1 | $59M | -19% | 1.0M | 58.07 |
|
| Janux Therapeutics (JANX) | 1.0 | $57M | -57% | 1.3M | 45.43 |
|
| Anthem (ELV) | 1.0 | $55M | -36% | 106k | 520.00 |
|
| Evolent Health Cl A Call Option (EVH) | 1.0 | $54M | -26% | 1.9M | 28.28 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.0 | $54M | -18% | 1.1M | 51.10 |
|
| Avidity Biosciences Ord (RNA) | 1.0 | $53M | +62% | 1.1M | 45.93 |
|
| Thermo Fisher Scientific (TMO) | 0.9 | $52M | -36% | 84k | 618.57 |
|
| Si-bone Call Option (SIBN) | 0.9 | $50M | +2% | 3.6M | 13.98 |
|
| Xtant Med Hldgs Com New (XTNT) | 0.9 | $49M | 73M | 0.68 |
|
|
| Regeneron Pharmaceuticals (REGN) | 0.9 | $48M | +98% | 45k | 1051.24 |
|
| EXACT Sciences Corporation (EXAS) | 0.8 | $46M | 680k | 68.12 |
|
|
| Springworks Therapeutics (SWTX) | 0.8 | $45M | -18% | 1.4M | 32.04 |
|
| Vaxcyte (PCVX) | 0.8 | $44M | -51% | 387k | 114.27 |
|
| Compass Therapeutics (CMPX) | 0.7 | $41M | 22M | 1.84 |
|
|
| Cytokinetics Com New (CYTK) | 0.7 | $41M | -5% | 767k | 52.80 |
|
| Syndax Pharmaceuticals (SNDX) | 0.7 | $37M | 1.9M | 19.25 |
|
|
| Corvus Pharmaceuticals (CRVS) | 0.7 | $37M | 6.9M | 5.28 |
|
|
| Apellis Pharmaceuticals (APLS) | 0.7 | $37M | -2% | 1.3M | 28.84 |
|
| Xenon Pharmaceuticals (XENE) | 0.7 | $36M | +5% | 911k | 39.37 |
|
| Universal Hlth Svcs CL B (UHS) | 0.6 | $36M | NEW | 156k | 229.01 |
|
| Icon SHS (ICLR) | 0.6 | $36M | -28% | 124k | 287.31 |
|
| Neurocrine Biosciences (NBIX) | 0.6 | $35M | -32% | 302k | 115.22 |
|
| Vera Therapeutics Cl A (VERA) | 0.5 | $30M | 676k | 44.20 |
|
|
| Bioage Labs | 0.5 | $30M | NEW | 1.4M | 20.80 |
|
| Scpharmaceuticals (SCPH) | 0.5 | $28M | +8% | 6.1M | 4.56 |
|
| Vir Biotechnology (VIR) | 0.5 | $27M | +54% | 3.6M | 7.49 |
|
| Phathom Pharmaceuticals (PHAT) | 0.5 | $26M | NEW | 1.4M | 18.08 |
|
| Cg Oncology (CGON) | 0.5 | $26M | NEW | 691k | 37.73 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.5 | $26M | +199% | 4.5M | 5.70 |
|
| Dyne Therapeutics (DYN) | 0.5 | $25M | 708k | 35.92 |
|
|
| Mineralys Therapeutics (MLYS) | 0.4 | $24M | 2.0M | 12.11 |
|
|
| Neuropace (NPCE) | 0.4 | $24M | 3.4M | 6.97 |
|
|
| Immatics SHS (IMTX) | 0.4 | $23M | 2.0M | 11.41 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 0.4 | $23M | -38% | 436k | 52.39 |
|
| Prelude Therapeutics (PRLD) | 0.4 | $23M | 11M | 2.07 |
|
|
| Apogee Therapeutics (APGE) | 0.4 | $22M | 379k | 58.74 |
|
|
| Ikena Oncology Nonvoting | 0.4 | $21M | 12M | 1.73 |
|
|
| Neumora Therapeutics (NMRA) | 0.4 | $20M | 1.5M | 13.21 |
|
|
| Acelyrin (SLRN) | 0.4 | $20M | 4.0M | 4.93 |
|
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.3 | $19M | NEW | 913k | 20.63 |
|
| Tyra Biosciences (TYRA) | 0.3 | $18M | 769k | 23.51 |
|
|
| Cullinan Oncology (CGEM) | 0.3 | $18M | -6% | 1.1M | 16.74 |
|
| Lexicon Pharmaceuticals Com New (LXRX) | 0.3 | $17M | +88% | 11M | 1.57 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.3 | $17M | +206% | 384k | 43.89 |
|
| Adicet Bio (ACET) | 0.3 | $17M | 11M | 1.44 |
|
|
| Medpace Hldgs (MEDP) | 0.3 | $15M | NEW | 45k | 333.80 |
|
| Adc Therapeutics Sa SHS (ADCT) | 0.3 | $14M | +5% | 4.5M | 3.15 |
|
| Gilead Sciences (GILD) | 0.2 | $13M | NEW | 152k | 83.84 |
|
| Biontech Se Sponsored Ads (BNTX) | 0.2 | $12M | NEW | 103k | 118.77 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.2 | $12M | NEW | 765k | 15.38 |
|
| Repare Therapeutics Ord (RPTX) | 0.2 | $11M | 3.3M | 3.44 |
|
|
| Abcellera Biologics (ABCL) | 0.2 | $11M | 4.2M | 2.60 |
|
|
| Pmv Pharmaceuticals (PMVP) | 0.2 | $9.6M | 6.5M | 1.49 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.2 | $9.2M | NEW | 967k | 9.50 |
|
| Verastem Com New (VSTM) | 0.2 | $8.6M | +87% | 2.9M | 2.99 |
|
| Lyell Immunopharma (LYEL) | 0.2 | $8.4M | -4% | 6.1M | 1.38 |
|
| Oscar Health Cl A (OSCR) | 0.1 | $7.5M | NEW | 352k | 21.21 |
|
| Bicara Therapeutics | 0.1 | $6.9M | NEW | 272k | 25.47 |
|
| Passage Bio (PASG) | 0.1 | $6.9M | -2% | 9.8M | 0.70 |
|
| Pepgen (PEPG) | 0.1 | $6.8M | NEW | 797k | 8.55 |
|
| Nkarta (NKTX) | 0.1 | $6.7M | +85% | 1.5M | 4.52 |
|
| Moderna Call Option (MRNA) | 0.1 | $6.7M | NEW | 100k | 66.83 |
|
| Ikena Oncology (IKNA) | 0.1 | $6.1M | 3.5M | 1.73 |
|
|
| Amicus Therapeutics (FOLD) | 0.1 | $6.1M | 570k | 10.68 |
|
|
| Scholar Rock Hldg Corp (SRRK) | 0.1 | $5.9M | -30% | 742k | 8.01 |
|
| Fate Therapeutics (FATE) | 0.1 | $5.9M | +23% | 1.7M | 3.50 |
|
| Inspiremd (NSPR) | 0.1 | $5.7M | 2.1M | 2.68 |
|
|
| Longboard Pharmaceuticals In (LBPH) | 0.1 | $5.7M | NEW | 170k | 33.33 |
|
| Tela Bio (TELA) | 0.1 | $5.5M | -12% | 2.2M | 2.53 |
|
| Solventum Corp Com Shs Call Option (SOLV) | 0.1 | $4.8M | -65% | 69k | 69.72 |
|
| X4 Pharmaceuticals (XFOR) | 0.1 | $4.8M | 7.1M | 0.67 |
|
|
| Krystal Biotech (KRYS) | 0.1 | $4.3M | -21% | 24k | 182.03 |
|
| Ardent Health Partners | 0.1 | $3.8M | NEW | 206k | 18.38 |
|
| Traws Pharma Com New | 0.1 | $3.6M | NEW | 606k | 5.88 |
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $3.0M | 2.0M | 1.52 |
|
|
| Cassava Sciences Put Option (SAVA) | 0.1 | $2.8M | NEW | 95k | 29.43 |
|
| Chemomab Therapeutics Sponsored Ads (CMMB) | 0.0 | $2.7M | -22% | 1.7M | 1.57 |
|
| Instil Bio Com New (TIL) | 0.0 | $2.3M | NEW | 34k | 67.32 |
|
| Biomx Com New | 0.0 | $1.8M | NEW | 1.8M | 1.02 |
|
| Geron Corporation Call Option (GERN) | 0.0 | $1.8M | -95% | 400k | 4.54 |
|
| Adagio Therapeutics (IVVD) | 0.0 | $1.8M | -28% | 1.7M | 1.02 |
|
| Turnstone Biologics Corp (TSBX) | 0.0 | $1.7M | 3.1M | 0.56 |
|
|
| Nextcure (NXTC) | 0.0 | $1.6M | 1.1M | 1.37 |
|
|
| Vigil Neuroscience (VIGL) | 0.0 | $1.5M | 449k | 3.40 |
|
|
| Kezar Life Sciences (KZR) | 0.0 | $1.5M | 1.9M | 0.77 |
|
|
| Elevation Oncology (ELEV) | 0.0 | $565k | 941k | 0.60 |
|
|
| Xeris Pharmaceuticals (XERS) | 0.0 | $229k | 80k | 2.85 |
|
Past Filings by Orbimed Advisors
SEC 13F filings are viewable for Orbimed Advisors going back to 2010
- Orbimed Advisors 2024 Q3 filed Nov. 14, 2024
- Orbimed Advisors 2024 Q2 filed Aug. 14, 2024
- Orbimed Advisors 2024 Q1 filed May 15, 2024
- Orbimed Advisors 2023 Q4 filed Feb. 14, 2024
- Orbimed Advisors 2023 Q3 filed Nov. 14, 2023
- Orbimed Advisors 2023 Q2 filed Aug. 14, 2023
- Orbimed Advisors 2023 Q1 filed May 15, 2023
- Orbimed Advisors 2022 Q4 filed Feb. 14, 2023
- Orbimed Advisors 2022 Q3 filed Nov. 14, 2022
- Orbimed Advisors 2022 Q2 filed Aug. 15, 2022
- Orbimed Advisors 2022 Q1 filed May 16, 2022
- Orbimed Advisors 2021 Q4 filed Feb. 14, 2022
- Orbimed Advisors 2021 Q3 filed Nov. 15, 2021
- Orbimed Advisors 2021 Q2 filed Aug. 16, 2021
- Orbimed Advisors 2021 Q1 filed May 17, 2021
- Orbimed Advisors 2020 Q4 filed Feb. 16, 2021